title: Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.
abstract: We analyzed cost-effectiveness studies related to hematologic malignancies from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), focusing on studies of innovative therapies. Studies that met inclusion criteria were categorized by 4 cancer types (chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma) and 9 treatment agents (interferon-α, alemtuzumab, bendamustine, bortezomib, dasatinib, imatinib, lenalidomide, rituximab alone or in combination, and thalidomide). We examined study characteristics and stratified cost-effectiveness ratios by type of cancer, treatment, funder, and year of study publication. Twenty-nine studies published in the years 1996-2012 (including 44 cost-effectiveness ratios) met inclusion criteria, 22 (76%) of which were industry funded. Most ratios fell below $50,000 per quality-adjusted life-years (QALY) (73%) and $100,000/QALY (86%). Industry-funded studies (n = 22) reported a lower median ratio ($26,000/QALY) than others (n = 7; $33,000/QALY), although the difference was not statistically significant. Published data suggest that innovative treatments for hematologic malignancies may provide reasonable value for money.
authors: Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA;
authors: Cayla J
authors: CJ
authors: Saret
authors: Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC; and.
authors: Aaron N
authors: AN
authors: Winn
authors: Center for Health Solutions, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
authors: Gunjan
authors: http://orcid.org/0000-0002-9977-0456
authors: G
authors: Shah
authors: Center for Health Solutions, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
authors: Susan K
authors: SK
authors: Parsons
authors: Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA;
authors: Pei-Jung
authors: PJ
authors: Lin
authors: Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA;
authors: Joshua T
authors: JT
authors: Cohen
authors: Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA;
authors: Peter J
authors: PJ
authors: Neumann
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003657:Decision Making; D004059:Diffusion of Innovation; D004470:Economics, Medical; D019337:Hematologic Neoplasms / Q000191:economics* / Q000628:therapy*; D006801:Humans; D018803:Models, Economic; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D012042:Registries; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
references: Turk J Haematol. 2013 Sep;30(3):247-55
references: 24385803
references: N Engl J Med. 2014 Aug 28;371(9):796-7
references: 25162885
references: Value Health. 2005 Jan-Feb;8(1):3-9
references: 15841889
references: JAMA. 1996 Oct 23-30;276(16):1339-41
references: 8861994
references: Lancet Oncol. 2011 Sep;12(9):837-8
references: 21984992
references: JAMA. 1996 Oct 16;276(15):1253-8
references: 8849754
references: Value Health. 2013 Mar-Apr;16(2):231-50
references: 23538175
references: Health Technol Assess. 2012;16(42):iii-iv, 1-277
references: 23134589
references: J Clin Oncol. 1997 Jul;15(7):2673-82
references: 9215840
references: J Natl Cancer Inst. 2010 Jan 20;102(2):82-8
references: 20056956
references: Blood. 2013 May 30;121(22):4439-42
references: 23620577
references: Leuk Lymphoma. 2013 Feb;54(2):229-41
references: 22897729
references: Eur J Haematol. 2010 Dec;85(6):484-91
references: 20846301
references: Eur J Cancer. 2009 May;45(7):1188-1192
references: 19138512
references: BMJ. 2006 Mar 25;332(7543):699-703
references: 16495332